Literature DB >> 3532329

Staging and kinetics of multiple myeloma.

B G Durie.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1986        PMID： 3532329

Source DB:  PubMed          Journal:  Semin Oncol        ISSN： 0093-7754            Impact factor:   4.929


× No keyword cloud information.
  34 in total

1.  Posttreatment nadir M-protein level is a stronger discriminator of survival following plateau attainment than is percent reduction in M-protein in patients with IgG myeloma.

Authors:  K Shimizu; E Nagura; N Hirabayashi; A Wakita; H Takeyama; H Sao; M Nitta; K Kawashima; H Saito
Journal:  Int J Hematol       Date:  2001-08       Impact factor: 2.490

2.  Serum levels of interleukin-6 in multiple myeloma and other hematological disorders: correlation with disease activity and other prognostic parameters.

Authors:  D M Nachbaur; M Herold; A Maneschg; H Huber
Journal:  Ann Hematol       Date:  1991 Feb-Mar       Impact factor: 3.673

3.  Phase II evaluation of bisantrene in refractory multiple myeloma. A Southwest Oncology Group study.

Authors:  B G Durie; J Crowley; C A Coltman; R A Chapman; S P Balcerzk; J D Bonnet; D A Lipschitz; R L Stephens; B D Cheson
Journal:  Invest New Drugs       Date:  1991-11       Impact factor: 3.850

4.  Comparison of whole-body 64-slice multidetector computed tomography and conventional radiography in staging of multiple myeloma.

Authors:  Patric Kröpil; Roland Fenk; Lars B Fritz; Dirk Blondin; Guido Kobbe; Ulrich Mödder; Mathias Cohnen
Journal:  Eur Radiol       Date:  2007-10-09       Impact factor: 5.315

5.  Low serum vitamin D occurs commonly among multiple myeloma patients treated with bortezomib and/or thalidomide and is associated with severe neuropathy.

Authors:  James Wang; Kyle A Udd; Aleksandra Vidisheva; Regina A Swift; Tanya M Spektor; Eric Bravin; Emad Ibrahim; Jonathan Treisman; Mohammed Masri; James R Berenson
Journal:  Support Care Cancer       Date:  2016-02-23       Impact factor: 3.603

6.  Combination therapy with thalidomide, incadronate, and dexamethasone for relapsed or refractory multiple myeloma.

Authors:  Naoya Ochiai; Noriko Yamada; Ryo Uchida; Shin-ichi Fuchida; Akira Okano; Mayumi Hatsuse; Masashi Okamoto; Eishi Ashihara; Chihiro Shimazaki
Journal:  Int J Hematol       Date:  2005-10       Impact factor: 2.490

7.  A novel flow cytometric assay for the quantification of adhesion of subsets within a heterogeneous cell population; analysis of lymphocyte function-associated antigen-1 (LFA-1)-mediated binding of bone marrow-derived primary tumour cells of patients with multiple myeloma.

Authors:  E J Ahsmann; R J Benschop; T D de Gruyl; J A Faber; H M Lokhorst; A C Bloem
Journal:  Clin Exp Immunol       Date:  1993-09       Impact factor: 4.330

Review 8.  Multiple myeloma. New treatment options.

Authors:  L Camba; B G Durie
Journal:  Drugs       Date:  1992-08       Impact factor: 9.546

9.  Bone morphogenic protein 6: a member of a novel class of prognostic factors expressed by normal and malignant plasma cells inhibiting proliferation and angiogenesis.

Authors:  A Seckinger; T Meissner; J Moreaux; H Goldschmidt; G M Fuhler; A Benner; M Hundemer; T Rème; J D Shaughnessy; B Barlogie; U Bertsch; J Hillengass; A D Ho; V Pantesco; A Jauch; J De Vos; J F Rossi; T Möhler; B Klein; D Hose
Journal:  Oncogene       Date:  2009-08-31       Impact factor: 9.867

10.  Close relation between 14q32/IGH translocations and chromosome 13 abnormalities in multiple myeloma: a high incidence of 11q13/CCND1 and 16q23/MAF.

Authors:  Madoka Takimoto; Kohei Ogawa; Yo Kato; Tasuku Saito; Takao Suzuki; Michiko Irei; Yasushi Shibuya; Yoshinori Suzuki; Masayuki Kato; Yasuyuki Inoue; Masatomo Takahashi; Hiroki Sugimori; Ikuo Miura
Journal:  Int J Hematol       Date:  2008-02-16       Impact factor: 2.490
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.